The "Validating Applications for Long-term Utility and Enhanced
ROI" (VALUE) in Cancer Risk Programs Study aims to bring together
health systems from across the country to advance understanding of
the system-level financial value of genetics and genomics.
CHICAGO, April 19,
2024 /PRNewswire-PRWeb/ -- CancerIQ, a best-in-class
cancer-focused precision health platform, today announced it is
seeking health systems to participate in the newly launched,
large-scale research effort that will document the downstream
revenue of digital interventions for genetically informed cancer
prevention, early detection and treatment. The "Validating
Applications for Long-term Utility and Enhanced ROI" (VALUE) in
Cancer Risk Programs Study aims to bring together health systems
from across the country to advance understanding of the
system-level financial value of genetics and genomics.
"For maximum benefit, health scientists
recommend integrating cancer genetics and genomics into everyday
patient care. This research seeks to bridge a critical knowledge
gap and demonstrate that genetics is a worthwhile investment to
drive positive clinical and financial outcomes."
Limited data exists on the net financial benefit of digitally
enabled cancer risk programs to the healthcare system, largely due
to the challenges of measuring downstream revenue and cost savings
from disease prevention, improved treatment efficacy and reduced
hospitalizations, among other factors. Measuring the ROI of
genetics programs is crucial to help allocate resources
efficiently, scale clinical impact and optimize technology
investments.
"For maximum benefit, health scientists recommend integrating
cancer genetics and genomics into everyday patient care," said
Jeffrey Weitzel, MD, principal
investigator of the VALUE in Cancer Risk Programs Study and
strategic advisor to CancerIQ. "This research seeks to bridge a
critical knowledge gap and demonstrate that genetics is a
worthwhile investment to drive positive clinical and financial
outcomes."
The VALUE in Cancer Risk Programs Study is led and organized by
CancerIQ. The company has previously demonstrated the ability to
extend the reach of cancer genetics clinicians, by doubling the
number of patients they can see while enhancing cancer risk
assessment, and improving overall cancer screening compliance rates
with its precision health platform. Last year, CancerIQ also
published two peer-reviewed papers illustrating the impact of
digital interventions on the uptake of genetics services by
patients.
"CancerIQ is committed to deploying cutting edge science-based
interventions that deliver tangible benefits to health systems and
patients," said Feyi Ayodele,
co-founder and CEO of CancerIQ. "We anticipate the VALUE in Cancer
Risk Programs Study will provide important insights to support the
expansion of lifesaving precision health resources."
The VALUE in Cancer Risk Programs Study invites health system
partners to contribute to this important research effort. To learn
more about how to participate, please email CancerIQ at
bd@canceriq.com or request a demo meeting at
canceriq.com/request-a-demo.
About CancerIQ
CancerIQ is the only cancer-focused precision health platform
that empowers healthcare providers to detect cancer earlier and
prevent it altogether across all patient populations. Integrated
directly into real-time EHR workflows, CancerIQ makes it easy to
gather comprehensive patient data, automatically map it to the
latest evidence-based guidelines, and expand access to personalized
care plans, cutting-edge clinical solutions, and genomic
innovations. CancerIQ co-founder and CEO Feyi Ayodele was recently named a Modern
Healthcare Innovator for pioneering this transformative approach to
cancer prevention, early detection and treatment. Learn more at
canceriq.com, follow CancerIQ on X or LinkedIn.
Contact
Malvina Kefalas
mkefalas@canceriq.com
(516) 503-8610
View original
content:https://www.prweb.com/releases/canceriq-launches-research-initiative-to-quantify-downstream-value-of-digitally-enabled-cancer-risk-programs-302121746.html
SOURCE CancerIQ